Welcome to our dedicated page for Ionis Pharmaceuticals SEC filings (Ticker: IONS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) SEC filings page on Stock Titan brings together the company’s regulatory disclosures from the U.S. Securities and Exchange Commission, along with AI-powered summaries to help interpret complex documents. As a biotechnology issuer focused on RNA-targeted medicines, Ionis uses filings such as Forms 8-K, 10-Q and 10-K to report clinical milestones, regulatory events, financing transactions and operating results.
Recent Form 8-K filings illustrate how Ionis communicates material developments. The company has furnished press releases on pivotal Phase 3 CORE and CORE2 results for olezarsen in severe hypertriglyceridemia, positive pivotal data for zilganersen in Alexander disease, and FDA approval of DAWNZERA (donidalorsen) for prophylaxis to prevent attacks of hereditary angioedema. Other 8-Ks describe FDA Breakthrough Therapy designations, European regulatory opinions and key clinical readouts across neurology and cardiometabolic programs.
Ionis also uses current reports to disclose capital markets activity. One 8-K details the issuance of 0.00% Convertible Senior Notes due 2030, including the terms of the indenture, conversion mechanics, redemption provisions, events of default and use of proceeds, such as repurchasing earlier convertible notes and funding general corporate purposes. Additional filings cover quarterly financial results, where the company presents both GAAP and non-GAAP measures, and governance or contractual matters like advisory services agreements.
On this page, Stock Titan connects directly to EDGAR to surface new Ionis filings as they are posted. AI-powered summaries help explain lengthy documents, highlighting items such as clinical trial outcomes, regulatory status updates, financing terms, risk factor changes and other key disclosures. Investors can quickly locate annual reports on Form 10-K, quarterly reports on Form 10-Q, current reports on Form 8-K and other relevant filings, and use the AI analysis to understand how each document may relate to Ionis’ RNA-targeted pipeline, marketed medicines and capital structure.
Ionis Pharmaceuticals executive Brian Birchler reported an employee stock purchase transaction. On February 27, 2026, he purchased 351 shares of Ionis common stock at an average price of $48.8665 per share under the company’s Amended and Restated 2000 Employee Stock Purchase Plan, bringing his direct holdings to 66,598 shares. These shares may not be sold until August 27, 2026.
Ionis Pharmaceuticals executive Frank Bennett, EVP and Chief Scientific Officer, reported a small personal share purchase through the company’s employee stock purchase plan. On February 27, 2026, he acquired 261 shares of Ionis common stock at $48.8665 per share under the Amended and Restated 2000 Employee Stock Purchase Plan.
Following this transaction, Bennett directly owns 100,554 common shares. According to the filing, these newly purchased shares are subject to a holding period and may not be sold until August 27, 2026, which temporarily restricts his ability to dispose of this specific block of stock.
Ionis Pharmaceuticals outlines its evolution into a fully integrated commercial-stage biotechnology company focused on RNA- and DNA-targeted medicines. The company now has seven marketed drugs, including TRYNGOLZA for familial chylomicronemia syndrome, DAWNZERA for hereditary angioedema, WAINUA for hereditary transthyretin amyloidosis, SPINRAZA for spinal muscular atrophy, QALSODY for SOD1-ALS, and TEGSEDI and WAYLIVRA for rare lipid and amyloid diseases.
Ionis is preparing two additional independent U.S. launches in 2026, assuming approval: olezarsen for severe hypertriglyceridemia (with FDA priority review and a PDUFA date of June 30, 2026) and zilganersen for Alexander disease, for which an NDA was submitted in January 2026. The company reported $944 million in revenue in 2025 and ended the year with $2.7 billion in cash, cash equivalents and short-term investments, supporting continued investment in its pipeline.
The business is underpinned by extensive global partnerships with AstraZeneca, Biogen, GSK, Novartis, Roche, Otsuka and others that provide royalties, milestones and shared development funding. Ionis also highlights a broad late- and mid-stage pipeline across neurology, cardiometabolic and rare diseases, and continued investment in next-generation technologies such as MsPA backbone chemistry, Bicycle- and Vect-Horus–enabled delivery and gene-editing collaborations.
Ionis Pharmaceuticals reported fourth-quarter and full-year 2025 results and issued 2026 guidance. Full-year revenue rose to $944 million from $705 million, driven by commercial growth and R&D collaboration revenue, including a $280 million upfront payment for sapablursen licensing.
TRYNGOLZA generated $108 million in 2025 net product sales in its first launch year, helping lift commercial revenue 49% year over year. Despite this growth, the company posted a 2025 GAAP net loss of $381 million and a non-GAAP operating loss of $248 million, both improved versus 2024.
Cash, cash equivalents and short-term investments increased to $2.7 billion as of December 31, 2025, aided by convertible debt refinancing. For 2026, Ionis guides to $800–$825 million in revenue, a non-GAAP operating loss of $500–$550 million, and year-end liquidity of about $1.6 billion, while continuing to invest in multiple independent launches and a broad late-stage pipeline.
T. Rowe Price Investment Management, Inc. filed an amended Schedule 13G reporting beneficial ownership of 9,108,019 shares of Ionis Pharmaceuticals common stock, representing 5.6% of the outstanding class as of the event date.
The firm reports sole voting power over 9,083,319 shares and sole dispositive power over 9,108,019 shares, with no shared voting or dispositive authority. It certifies the shares were acquired and are held in the ordinary course of business, not for the purpose of changing or influencing control of Ionis Pharmaceuticals, and includes a legal disclaimer that it is not admitting beneficial ownership.
Ionis Pharmaceuticals executive files corrective Form 4/A. EVP and Chief Scientific Officer C. Frank Bennett reports that an earlier filing on February 4, 2026 mistakenly showed a sale of 20,000 common shares and the exercise of 65,089 stock options. These transactions were executed in error and fully reversed on February 12, 2026.
Following the reversal, Bennett is shown as directly beneficially owning 100,293 shares of Ionis Pharmaceuticals common stock as of February 12, 2026. The current filing uses a corrective "J" transaction code with zero shares at a price of $0.0 to document the adjustment.
Ionis Pharmaceuticals EVP Research Eric Swayze reported preset stock sales. On February 13, 2026, he executed two open-market sales of Ionis common stock under a Rule 10b5-1 trading plan adopted on August 14, 2024.
The transactions totaled 9,435 shares at $81.5592 and 6,207 shares at $82.0691 weighted-average prices. After these sales, Swayze held 32,105 shares directly and 318 shares indirectly through his son.
Ionis Pharmaceuticals director B. Lynne Parshall reported an open-market sale of common stock. On February 11, 2026, Parshall sold 5,000 shares of Ionis common stock at a weighted average price of $82.7177 per share under a pre-established Rule 10b5-1 trading plan adopted on May 6, 2025. After this transaction, Parshall directly beneficially owns 56,344 shares of Ionis common stock.
Ionis Pharmaceuticals shareholder Eric Swayze has filed a notice of proposed sale of 15,642 shares of common stock under Rule 144. The shares, to be sold through Stifel Nicolaus & Company Inc. on Nasdaq around 02/13/2026, have an aggregate market value of $1,277,169.00. The filing notes that 161,974,393 shares of Ionis common stock were outstanding. These 15,642 shares were acquired on 01/15/2026 as restricted stock units granted by the issuer as equity compensation. Over the prior three months, Swayze sold additional Ionis common stock in three transactions totaling 39,526 shares for gross proceeds of $3,122, - combining reported amounts of $1,853,577.00, $753,501.00, and $512,906.00.
Ionis Pharmaceuticals (symbol IONS) has an insider planning to sell 10,000 shares of common stock through broker Stifel Nicolaus & Company on or around February 11, 2026 on the Nasdaq market. The filing lists an aggregate market value of $827,400 for these planned sales.
The securities relate to common stock originally acquired on January 15, 2017 as restricted stock units granted by the issuer as equity compensation. The notice also states that the person signing does not know of any undisclosed material adverse information about the issuer’s current or prospective operations.